Methods of treating neurological and psychiatric disorders
The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.
1. A method of treating a neurological or psychiatric disease or disorder without decreasing sleep quality in a human patient in need thereof, comprising once daily orally administering to the patient a therapeutically effective amount of from 25 to 100 mg of Compound 1
or a pharmaceutically acceptable salt thereof at about bedtime.
2. The method of claim 1 , wherein the therapeutically effective amount comprises from 25 to 75 mg.
3. The method of claim 1 , wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.
4. The method of claim 1 , wherein the administration produces a C trough of 7.97-31.5 ng/mL after multiple administrations.
5. The method of claim 1 , wherein the administration produces a t max of 2.0-4.0 hours after single or multiple administrations.
6. The method of claim 1 , for treating the neurological or psychiatric disease or disorder in the patient continuously for a period of 6 months or more, comprising administering the therapeutically effective amount for 6 months or more.
7. A method of treating a neurological or psychiatric disease or disorder, in a human patient in need thereof, comprising once-daily administering to the patient a therapeutically effective amount of Compound 1
or a pharmaceutically acceptable salt thereof at about bedtime, so as to produce a t max of 2.0-4.0 hours after single or multiple administrations.
8. The method of claim 7 , wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.
9. The method of claim 7 , wherein the therapeutically effective amount comprises from 25 to 75 mg.
10. The method of claim 7 , wherein the administration produces a C trough of 7.97-31.5 ng/mL after multiple administrations.
11. The method of claim 7 , for treating the neurological or psychiatric disease or disorder in the patient continuously for a period of 6 months or more, comprising administering the therapeutically effective amount for 6 months or more.
12. The method of claim 7 , wherein the neurologic or psychiatric disease or disorder is schizophrenia in a patient having a PANSS total score <80.
13. The method of claim 7 , wherein the neurologic or psychiatric disease or disorder is depression.
14. The method of claim 7 , wherein the neurologic or psychiatric disease or disorder is anxiety.
15. The method of claim 11 , wherein the neurologic or psychiatric disease or disorder is schizophrenia in a patient having a PANSS total score <80.
16. The method of claim 11 , wherein the neurologic or psychiatric disease or disorder is depression.
17. The method of claim 11 , wherein the neurologic or psychiatric disease or disorder is anxiety.
18. A method of treating a neurological or psychiatric disease or disorder, in a human patient in need thereof, comprising once-daily administering to the patient a therapeutically effective amount of Compound 1
or a pharmaceutically acceptable salt thereof at about bedtime, so as to produce a C trough of 7.97-31.5 ng/mL after multiple administrations.
19. The method of claim 18 , wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.
20. The method of claim 18 , wherein the therapeutically effective amount comprises from 25 to 75 mg.
21. The method of claim 18 , for treating the neurological or psychiatric disease or disorder in the patient continuously for a period of 6 months or more, comprising administering the therapeutically effective amount for 6 months or more.